title: [Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
abstract: Abiraterone acetate (AA) is a selective inhibitor of cytochrom p450 (CYP)17 which is required for androgen biosynthesis, and can block the androgens synthesis by testicles, surrenals and intratumoral secretion. In phase I and II studies in patients with prostate cancer, therapy with AA 250-2000  mg once daily demonstrated reductions in prostate specific antigen (PSA), and/or circulating tumor cells (CTCs). In two large phase III trials in patients with metastatic castration resistant prostate cancer (CRPC) in post-docetaxel and pre-docetaxel setting, AA plus prednisone compared with placebo plus prednisone demonstrated a significant superior overall survival in post-docetaxel setting, and a superior radiological PFS in pre-docetaxel setting. Based of these results, AA is approved in metastatic CRPC patients in post-docetaxel setting or pre-docetaxel setting in 2013.
authors.affiliation: Institut Gustave-Roussy, DITEP, Département d'innovations thérapeutiques et essais précoces, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France.
authors.forename: Emilie
authors.initials: E
authors.lastname: Boissier
authors.affiliation: Institut Gustave-Roussy, Département de médecine oncologique, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France.
authors.forename: Yohann
authors.initials: Y
authors.lastname: Loriot
authors.affiliation: Service d'oncologie et hématologie, 4, rue Louis-Pasteur, 28630 Chartres Le Coudray, France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Vignot
authors.affiliation: Institut Gustave-Roussy, DITEP, Département d'innovations thérapeutiques et essais précoces, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Massard
mesh_terms: D000069501:Abiraterone Acetate; D000730:Androstadienes / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D009360:Neoplastic Cells, Circulating; D011241:Prednisone / Q000627:therapeutic use; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors*; D043823:Taxoids / Q000627:therapeutic use
chemical_list: D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D043823:Taxoids; D000077143:Docetaxel; D013254:Steroid 17-alpha-Hydroxylase; D017430:Prostate-Specific Antigen; D000069501:Abiraterone Acetate; D011241:Prednisone
keywords: abiraterone acetate; castration-resistance prostate cancer; cytochrome CYP17; steroidogenosis